Zephyr Group, Inc.: Investing in the Future of Healthspan

Bridging the Gap Between Nature and Modern Bioscience

The Core Thesis: "Life to Years"

Zephyr Group, Inc. is an emerging biotechnology company dedicated to healthspan optimization. We are moving beyond the "reactive" healthcare model to develop evidence-based solutions at the intersection of therapeutic peptides, high-potency phytoceuticals, and advanced delivery systems.

The Zephyr Identity: Precision. Longevity. Patented.

The Problem: A Reactive Healthcare Crisis

Modern medicine is designed for late-stage intervention. We treat chronic conditions after they appear, rather than addressing the root causes of aging and metabolic decline. Furthermore, the "natural" supplement market is plagued by:

• Bioavailability Gaps: Active compounds that are poorly absorbed by the body.
• Transparency Void: Lack of consistent quality and scientific rigor.
• Scientific Stagnation: Products that fail to evolve alongside modern biotechnology.

The Solution: The Zephyr Convergence Platform

Zephyr bridges the gap between nature-based compounds and pharmaceutical-grade science. Our platform-first strategy ensures that every product is:

1. Synergistic: Pairing signaling peptides with plant-derived actives for multi-target efficacy.
2. Highly Bioavailable: Utilizing liposomal and exosomal delivery to ensure compounds reach their cellular targets.
3. Validated: A rigorous commitment to clinical data and quality control.

Product Pipeline: Targeting the Metabolic Revolution

With the global shift toward metabolic health and GLP-1 awareness, Zephyr is positioned with high-demand assets:

Asset	Target	Status
Z-Metabolic Lead	Type II Diabetes/Blood Glucose	Positive early data on HbA1c & lipids
Z-GLP-1 Natural	Satiety & Weight Management	Market-ready formulation
Next-Gen Delivery	Nutrient/Peptide Absorption	In development (Exosomal focus)

Why Now? Converging Tailwinds

We are at the "Golden Age" of longevity science. Investors are increasingly looking for alternatives to traditional pharma that offer:

• Preventative Focus: A massive shift toward personalized wellness.
• Metabolic Awareness: Global demand for weight-management and glucose-stability solutions.
• Validated Innovation: The rise of "Science-Backed Wellness" as a distinct, high-growth asset class.

Use of Proceeds: From Foundation to Acceleration

This Reg-CF offering is a strategic step to fuel our disciplined growth.

At Minimum Target:

• Regulatory Compliance: Solidifying our legal and financial foundations.
• Investor Relations: Scaling communications and transparency.
• Foundational Marketing: Building the brand architecture for commercial launch.

At Maximum Target:

• Reg A+ Preparation: Setting the stage for a larger institutional-grade raise.
• Accelerated Commercialization: Rapidly bringing our GLP-1 and Metabolic assets to market.
• M&A Evaluation: Identifying strategic acquisitions to expand our IP portfolio.

Rooted in Conviction

Founded in 2021, Zephyr Group was born from a personal realization: Prevention is the only sustainable path. Our leadership team combines healthcare experience with a relentless focus on integrity and accountability. We aren't just building products; we are building a standard for the longevity industry.

---

Early Investor Incentive – Clinical Catalyst Bonus

To recognize early supporters of the offering, the Company is offering a Tier 1 Early Investment Incentive referred to as the Clinical Catalyst Principal Bonus.

Eligibility - Investors whose investments are funded and cleared within the first $250,000 of accepted investments in this offering will be eligible for the incentive, on a first-funded basis.

Incentive Terms - Eligible investors will receive a 10% Principal Bonus, meaning that the principal amount of their investment will be increased by 10% solely for purposes of calculating the number of securities issued upon conversion.

Example - An investor who invests $1,000 and qualifies for the incentive will have their investment recorded as a $1,100 principal amount for purposes of conversion into securities under the terms of the Note.

Important Notes

• The Principal Bonus applies only to investments that are accepted and funded while the first $250,000 incentive allocation remains available.

• Once the Tier 1 allocation is fully subscribed, subsequent investors will not receive this incentive.

• The bonus increases the conversion principal amount only and does not represent additional cash proceeds paid by the investor.

• All incentives are subject to the terms described in the Form C.

---

Join the Mission.

Review our full offering details and risk factors on the campaign page to see if your vision for the future of health aligns with ours.